PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1657-1662

  Vincenzi, Bruno ^a   Santini, Daniele ^a   Schiavon, Gaia ^a   Frezza, Anna Maria ^a   Silletta, Marianna ^a   Crucitti, Pierfilippo ^a   Casali, Paolo ^b   Tos, Angelo P Dei ^c   Rossi, Sabrina ^c   Rizzo, Sergio ^d   Badalamenti, Giuseppe ^d   Tomasino, Rosa Maria ^e   Russo, Antonio ^d   Butrynski, James E ^f   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c GENERAL HOSPITAL   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f Dana Farber Cancer Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; IFOSFAMIDE; PROMYELOCYTIC LEUKEMIA PROTEIN;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLASTIC SARCOMA; MYXOSARCOMA; PLEOMORPHIC ADENOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, ALKYLATING; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84855744818     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22889     Document Type: Article

References (28)

1. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP. 2006. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442:779-785.
2. Clark MA, Fisher C, Judson I, Thomas JM. 2005. Soft-tissue sarcomas in adults. N Engl J Med 353:701-711.
3. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. 2001. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. Embo J 20:4547-4559.
4. Cox DR. 1972. Regression models and life tables. J R Stat Soc B 34:187-220.
5. Culjkovic B, Topisirovic I, Borden KL. 2007. Controlling gene expression through RNA regulons: The role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6:65-69.
6. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14:2015-2027.
7. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96:269-279.
8. Halazonetis TD, Gorgoulis VG, Bartek J. 2008. An oncogene-induced DNA damage model for cancer development. Science 319:1352-1355.
9. Huang HY, West RB, Tzeng CC, van de Rijn M, Wang JW, Chou SC, Huang WW, Eng HL, Lin CN, Yu SC, Wu JM, Lu CC, Li CF. 2008. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: The potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. Clin Cancer Res 14:6023-6032.
10. Kaplan E, Meier P. 1958. Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
11. Kurki S, Latonen L, Laiho M. 2003. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci 116:3917-3925.
12. Le XF, Yang P, Chang KS. 1996. Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J Biol Chem 271:130-135.
13. Lee HE, Jee CD, Kim MA, Lee HS, Lee YM, Lee BL, Kim WH. 2007. Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett 247:103-109.
14. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ, Chen JD. 2000. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol 20:1784-1796.
15. Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O, Ferbeyre G. 2004. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23:91-99.
16. Melnick A, Licht JD. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
17. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Droge W, Will H, Schmitz ML. 2003. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63:4310-4314.
18. Mu ZM, Le XF, Vallian S, Glassman AB, Chang KS. 1997. Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis 18:2063-2069.
19. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 35:1-39.
20. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK. (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
21. Salomoni P, Bellodi C. 2007. New insights into the cytoplasmic function of PML. Histol Histopathol 22:937-946.
22. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. 2005. The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 105:3686-3690.
23. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol Cell 24:331-339.
24. Torii S, Egan DA, Evans RA, Reed JC. 1999. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). Embo J 18:6037-6049.
25. Vincenzi B, Santini D, Perrone G, Russo A, Adamo V, Rizzo S, Castri F, Antinori A, Alloni R, Crucitti PF, Morini S, Rabitti C, Vecchio FM, Magistrelli P, Coppola R, Tonini G. 2009. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients. Ann Oncol 20:78-83.
26. Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. 2010. PML down-regulation in soft tissue sarcomas. J Cell Physiol 224:644-648.
27. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. 1998. PML is essential for multiple apoptotic pathways. Nat Genet 20:266-272.
28. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, Schwanitz G, Hoischen C, Maul G, Dittrich P, Hemmerich P. 2008. Dynamics of component exchange at PML nuclear bodies. J Cell Sci 121:2731-2743.